Article
Medicine, General & Internal
Eric J. Lenze, Benoit H. Mulsant, Steven P. Roose, Helen Lavretsky, Charles F. Reynolds, Daniel M. Blumberger, Patrick J. Brown, Pilar Cristancho, Alastair J. Flint, Marie A. Gebara, Torie R. Gettinger, Emily Lenard, J. Philip Miller, Ginger E. Nicol, Hanadi A. Oughli, Vy T. Pham, Bruce L. Rollman, Lei Yang, Jordan F. Karp
Summary: In this study, a two-step open-label trial was conducted to investigate the effects of augmenting or switching antidepressants in older adults with treatment-resistant depression. The results showed that augmenting existing antidepressants with aripiprazole significantly improved well-being compared to switching to bupropion. Furthermore, augmentation with lithium or a switch to nortriptyline showed similar effects in patients who did not benefit from augmentation or a switch to bupropion. These findings highlight the potential benefits of aripiprazole augmentation in the treatment of treatment-resistant depression in older adults.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
E. J. Lenze, B. H. Mulsant, S. P. Roose, H. Lavretsky, C. F. Reynolds, D. M. Blumberger, P. J. Brown, P. Cristancho, A. J. Flint, M. A. Gebara, T. R. Gettinger, E. Lenard, J. P. Miller, G. E. Nicol, H. A. Oughli, V. T. Pham, B. L. Rollman, L. Yang, J. F. Karp
Summary: This study investigated the benefits and risks of augmenting or switching antidepressants in older adults with treatment-resistant depression. The study found that augmenting existing antidepressants with aripiprazole significantly improved psychological well-being compared to switching to bupropion. Among patients in whom augmentation or a switch to bupropion failed, the effects on psychological well-being and remission were similar with lithium augmentation or a switch to nortriptyline.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Clinical Neurology
Ju-Wei Hsu, Li-Chi Chen, Shih-Jen Tsai, Kai-Lin Huang, Ya-Mei Bai, Tung-Ping Su, Tzeng-Ji Chen, Mu -Hong Chen
Summary: Studies have shown that there is a positive relationship between resistance to antidepressants and the progression of bipolar disorder. However, the specific influence of different types of antidepressants, such as SSRIs and SNRIs, in this context has not been thoroughly investigated. This study recruited a total of 5,285 young people with antidepressant-resistant depression and 21,140 with antidepressant-responsive depression. It was found that those with resistance to antidepressants, especially to both SSRIs and SNRIs, were at an increased risk of developing bipolar disorder.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Ma-Li Wong, Mauricio Arcos-Burgos, Sha Liu, Alice W. Licinio, Chenglong Yu, Eunice W. M. Chin, Wei-Dong Yao, Xin-Yun Lu, Stefan R. Bornstein, Julio Licinio
Summary: Rare functional variants were identified in antidepressant drug response, serving as potential genetic markers for predicting drug response. Limitations include small sample size and inability to use antidepressant blood level as a covariate. Further studies with larger cohorts are warranted.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Psychiatry
Jae-Min Kim, Hee-Ju Kang, Ju-Wan Kim, Wonsuk Choi, Ju-Yeon Lee, Sung -Wan Kim, Il-Seon Shin
Summary: The roles of inflammatory markers in predicting the response to antidepressants are controversial, with levels increasing with age. Higher hsCRP levels were associated with non-remission in younger patients, but not older patients. However, higher IL-18 and IL-6 levels were associated with non-remission in all patients, regardless of age. The associations between inflammatory markers and remission differed depending on patient age, emphasizing the importance of considering age when predicting antidepressant response based on serum hsCRP level.
PSYCHIATRY RESEARCH
(2023)
Article
Clinical Neurology
Ju-Wei Hsu, Li-Chi Chen, Kai-Lin Huang, Shih-Jen Tsai, Ya-Mei Bai, Tung-Ping Su, Tzeng-Ji Chen, Mu-Hong Chen
Summary: Compared to adolescents with antidepressant-responsive depression, those with antidepressant-resistant depression have a higher risk of developing type 2 diabetes mellitus. Clinicians should closely monitor risk factors related to type 2 diabetes in high-risk populations, especially in adolescents with antidepressant-resistant depression.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Neurosciences
Cheng-Ta Li, Tung-Ping Su, Chih-Ming Cheng, Mu-Hong Chen, Ya-Mei Bai, Shih-Jen Tsai
Summary: Several clinical variables, such as the number of psychiatric admissions, comorbidity of OCD, and life stress level, were reliable predictors of antidepressant responses to rTMS treatment and can be used in conjunction with MSM subitems to evaluate levels of treatment-resistant depression (TRD).
FRONTIERS IN NEUROSCIENCE
(2022)
Article
Clinical Neurology
Hsin-Jung Tsai, Wei-Cheng Yang, Shih-Jen Tsai, Ching-Hua Lin, Albert C. Yang
Summary: This study found that the homogeneity of frontal-central alpha complexity and normalization of interhemispheric asymmetry in anterior EEG complexity are associated with antidepressant efficacy in patients with major depression.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Sjoerd M. van Belkum, Marrit K. de Boer, Esther M. Opmeer, Rudie Kortekaas, Tim Mulder, Frank Woonings, H. J. Rogier Hoenders, Hans Kamphuis, Andre Aleman, Robert A. Schoevers
Summary: The active tPEMF treatment for TRD patients did not show superiority over sham in short- and long-term efficacy, with no significant differences between the two groups in terms of changes in depressive symptoms post-treatment or any secondary measures. The study highlighted the importance of considering different dosing regimens in future research.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Health Care Sciences & Services
Chih-Ken Chen, Lawrence Shih-Hsin Wu, Ming-Chyi Huang, Chian-Jue Kuo, Andrew Tai-Ann Cheng
Summary: This study investigates the effects of individual genomics and antidepressant medication on the risk of manic switch in bipolar I disorder. The results suggest that the rs10262219 variant on chromosome 7 and antidepressant treatment significantly increase the risk of manic switch after bipolar depression.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Psychiatry
Balwinder Singh, Siamak MahmoudianDehkordi, Jennifer L. Vande Voort, Xianlin Han, John D. Port, Mark A. Frye, Rima Kaddurah-Daouk
Summary: In this pilot study, new insights into the mechanism of action of ketamine were highlighted. The study demonstrated that ketamine rapidly utilizes short-chain acylcarnitines and has broad effects on lipid metabolism, including changes in triglyceride levels. These findings provide novel insights into the action of ketamine and suggest a possible role for mitochondrial function and energy metabolism.
PSYCHIATRY RESEARCH
(2022)
Article
Clinical Neurology
Jessica R. Gilbert, Jessica L. Gerner, Courtney R. Burton, Allison C. Nugent, Carlos A. Zarate, Elizabeth D. Ballard
Summary: This study investigated the magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD), both at baseline and after subanesthetic-dose ketamine infusion. The findings showed that ketamine significantly reduced SI and depression in the sample. Following ketamine infusion, attempters showed improved accuracy on the task, while non-attempters showed reduced accuracy. SI was positively associated with gamma power in frontal and parietal cortices. In an extended amygdalahippocampal region, attempters differed significantly in their emotional reactivity to angry versus happy faces as indexed by theta power differences, regardless of drug. Ketamine also reduced the association between alpha power and SI for angry compared to happy faces in a fronto-insular/anterior cingulate region important for regulating sensory attentiveness.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Christophe Moderie, Nicolas Nunez, Allan Fielding, Stefano Comai, Gabriella Gobbi
Summary: This study found that women with TRD responded significantly better to augmentation therapy compared to men, especially in terms of symptoms like insomnia and anxiety. This highlights the importance of considering gender differences in treatment strategies for depression.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Masaki Kato, Hikaru Hori, Takeshi Inoue, Junichi Iga, Masaaki Iwata, Takahiko Inagaki, Kiyomi Shinohara, Hissei Imai, Atsunobu Murata, Kazuo Mishima, Aran Tajika
Summary: Continuing treatment with antidepressants after achieving remission is recommended to reduce the risk of relapse of depressive symptoms. Different classes of antidepressants have varying effectiveness in preventing relapse, with tricyclics showing the highest effect size. Maintenance therapy for at least 6 months is crucial for relapse prevention.
MOLECULAR PSYCHIATRY
(2021)
Article
Neurosciences
Marion Psomiades, Marine Mondino, Filipe Galvao, Nathalie Mandairon, Mikail Nourredine, Marie-Francoise Suaud-Chagny, Jerome Brunelin
Summary: This study found that the level of mature BDNF (mBDNF) is associated with the efficacy of electroconvulsive therapy (ECT) for patients with treatment-resistant depression. Patients with higher baseline mBDNF levels were more likely to achieve remission after ECT sessions.
Article
Psychiatry
George I. Papakostas, Richard C. Shelton, John M. Zajecka, Bijan Etemad, Karl Rickels, Alisabet Clain, Lee Baer, Elizabeth D. Dalton, Garret R. Sacco, David Schoenfeld, Michael Pencina, Allison Meisner, Teodoro Bottiglieri, Erik Nelson, David Mischoulon, Jonathan E. Alpert, James G. Barbee, Sidney Zisook, Maurizio Fava
AMERICAN JOURNAL OF PSYCHIATRY
(2012)
Article
Pharmacology & Pharmacy
Charu Taneja, George I. Papakostas, Yonghua Jing, Ross A. Baker, Robert A. Forbes, Gerry Oster
ANNALS OF PHARMACOTHERAPY
(2012)
Review
Psychiatry
George I. Papakostas, Clair F. Cassiello, Nadia Iovieno
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2012)
Article
Clinical Neurology
David Mischoulon, Stefania Lamon-Fava, Jacob Selhub, Judith Katz, George I. Papakostas, Dan V. Iosifescu, Albert S. Yeung, Christina M. Dording, Amy H. Farabaugh, Alisabet J. Clain, Lee Baer, Jonathan E. Alpert, Andrew A. Nierenberg, Maurizio Fava
Article
Psychology, Clinical
Maren Nyer, Amy Farabaugh, Kiki Fehling, David Soskin, Daphne Holt, George I. Papakostas, Paola Pedrelli, Maurizio Fava, Angela Pisoni, Ottavio Vitolo, David Mischoulon
DEPRESSION AND ANXIETY
(2013)
Article
Clinical Neurology
George H. Papakostas, Hua Fan, Enrico Tedeschini
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2012)
Article
Psychiatry
C. M. Dording, D. Mischoulon, I. Shyu, J. E. Alpert, G. I. Papakostas
EUROPEAN PSYCHIATRY
(2012)
Article
Psychiatry
Y. Levkovitz, J. E. Alpert, C. E. Brintz, D. Mischoulon, G. I. Papakostas
EUROPEAN PSYCHIATRY
(2012)
Article
Pharmacology & Pharmacy
Michael E. Thase, Stuart Montgomery, George I. Papakostas, Michael Bauer, Madhukar H. Trivedi, Henrik Svedsaeter, Julie C. Locklear, Urban Gustafsson, Catherine Datto, Hans Eriksson
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2013)
Article
Psychology, Clinical
David Mischoulon, Janet Witte, Michael Levy, George I. Papakostas, L. Russell Pet, Wen-hua Hsieh, Michael J. Pencina, Sean Ward, Mark H. Pollack, Maurizio Fava
JOURNAL OF CLINICAL PSYCHIATRY
(2012)
Review
Psychology, Clinical
Nadia Iovieno, George I. Papakostas
JOURNAL OF CLINICAL PSYCHIATRY
(2012)
Article
Psychology, Clinical
George I. Papakostas, Ottavio V. Vitolo, Waguih W. IsHak, Mark H. Rapaport, John M. Zajecka, Gustavo Kinrys, David Mischoulon, Samuel H. Lipkin, Katherine A. Hails, Jonah Abrams, Sean G. Ward, Allison Meisner, David A. Schoenfeld, Richard C. Shelton, Andrew Winokur, Mahmoud S. Okasha, Mohammed A. Bari, Maurizio Fava
JOURNAL OF CLINICAL PSYCHIATRY
(2012)
Article
Psychology, Clinical
David Mischoulon, Jonathan E. Alpert, Erland Arning, Teodoro Bottiglieri, Maurizio Fava, George I. Papakostas
JOURNAL OF CLINICAL PSYCHIATRY
(2012)
Article
Psychology, Clinical
Nadia Iovieno, George I. Papakostas
JOURNAL OF CLINICAL PSYCHIATRY
(2012)
Article
Biochemistry & Molecular Biology
G. I. Papakostas, R. C. Shelton, G. Kinrys, M. E. Henry, B. R. Bakow, S. H. Lipkin, B. Pi, L. Thurmond, J. A. Bilello
MOLECULAR PSYCHIATRY
(2013)
Review
Neurosciences
Maya Jammoul, Dareen Jammoul, Kevin K. Wang, Firas Kobeissy, Ralph G. Depalma
Summary: This article reviews the possible mechanisms by which traumatic brain injury (TBI) may stimulate the development of opioid use disorder (OUD) and discusses the interaction between these two processes. CNS damage due to TBI appears to drive adverse effects of subsequent OUD, with pain being a risk factor for opioid use after TBI.
BIOLOGICAL PSYCHIATRY
(2024)
Article
Neurosciences
Danusa Mar Arcego, Jan-Paul Buschdorf, Nicholas O'Toole, Zihan Wang, Barbara Barth, Irina Pokhvisneva, Nirmala Arul Rayan, Sachin Patel, Euclides Jose de Mendonca Filho, Patrick Lee, Jennifer Tan, Ming Xuan Koh, Chu Ming Sim, Carine Parent, Randriely Merscher Sobreira de Lima, Andrew Clappison, Kieran J. O'Donnell, Carla Dalmaz, Janine Arloth, Nadine Provencal, Elisabeth B. Binder, Josie Diorio, Patricia Pelufo Silveira, Michael J. Meaney
Summary: This study investigates the impact of environmental influences on mental health by integrating transcriptomic data from animal models with human data. The results suggest that hippocampal glucocorticoid-related transcriptional activity mediates the effects of early adversity on neural mechanisms implicated in psychiatric disorders.
BIOLOGICAL PSYCHIATRY
(2024)
Article
Neurosciences
Milenna T. van Dijk, Ardesheer Talati, Pratik Kashyap, Karan Desai, Nora C. Kelsall, Marc J. Gameroff, Natalie Aw, Eyal Abraham, Breda Cullen, Jiook Cha, Christoph Anacker, Myrna M. Weissman, Jonathan Posner
Summary: This study found that maternal stress is associated with future depressive symptoms and alterations in microstructure of the dentate gyrus (DG) in offspring. These results were consistent across two independent cohorts.
BIOLOGICAL PSYCHIATRY
(2024)
Article
Neurosciences
Josephine C. McGowan, Liliana R. Ladner, Claire X. Shubeck, Juliana Tapia, Christina T. LaGamma, Amanda Anqueira-Gonzalez, Ariana DeFrancesco, Briana K. Chen, Holly C. Hunsberger, Ezra J. Sydnor, Ryan W. Logan, Tzong-Shiue Yu, Steven G. Kernie, Christine A. Denny
Summary: Traumatic brain injury (TBI) leads to fear generalization by altering fear memory traces, and this symptom can be improved with (R,S)-ketamine.
BIOLOGICAL PSYCHIATRY
(2024)